Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Clemens

Showing results (331-340 of 434) with videos related to

Pageof 44
Sort By:
The Journal of Infectious Diseases|September 28, 2001
Level of maternal antibody required to protect neonates against early-onset disease caused by group B Streptococcus type Ia: a multicenter, seroepidemiology studyF Y Lin, J B Philips, P H Azimi, et al.
Zhonghua Liu Xing Bing Xue Za Zhi = Zhonghua Liuxingbingxue Zazhi|September 20, 2007
[Evaluation on the safety of a group A + C meningococcal polysaccharide vaccine]Bai-qing Dong, Qiang Ye, Xuan-lin Cui, et al.
Heliyon|July 23, 2020
The epidemiology of dengue outbreaks in 2016 and 2017 in Ouagadougou, Burkina FasoJustin Im, Ruchita Balasubramanian, Moussa Ouedraogo, et al.
The Journal of Infectious Diseases|December 8, 1998
Oral, inactivated, whole cell enterotoxigenic Escherichia coli plus cholera toxin B subunit vaccine: results of the initial evaluation in children. PRIDE Study GroupS J Savarino, E R Hall, S Bassily, et al.
Journal of Medical Microbiology|January 26, 2006
Multilocus sequence typing (MLST) analysis of Vibrio cholerae O1 El Tor isolates from Mozambique that harbour the classical CTX prophageJe Hee Lee, Kyung Ho Han, Seon Young Choi, et al.
The Pediatric Infectious Disease Journal|June 22, 2002
Introductory evaluation of an oral, killed whole cell enterotoxigenic Escherichia coli plus cholera toxin B subunit vaccine in Egyptian infantsStephen J Savarino, Eric R Hall, Samir Bassily, et al.
Statistics in Medicine|August 24, 2021
A Bayesian approach for estimating typhoid fever incidence from large-scale facility-based passive surveillance dataMaile T Phillips, James E Meiring, Merryn Voysey, et al.
BMC Infectious Diseases|May 17, 2019
Safety of a bivalent, killed, whole-cell oral cholera vaccine in pregnant women in Bangladesh: evidence from a randomized placebo-controlled trialAshraful Islam Khan, Mohammad Ali, Julia Lynch, et al.
Plos Neglected Tropical Diseases|March 13, 2015
Flexibility of oral cholera vaccine dosing-a randomized controlled trial measuring immune responses following alternative vaccination schedules in a cholera hyper-endemic zoneSuman Kanungo, Sachin N Desai, Ranjan Kumar Nandy, et al.
Plos Neglected Tropical Diseases|February 12, 2014
Mass vaccination with a new, less expensive oral cholera vaccine using public health infrastructure in India: the Odisha modelShantanu K Kar, Binod Sah, Bikash Patnaik, et al.
Pageof 44

Showing results (331-340 of 434) with videos related to

Sort By:
Pageof 44
The Journal of Infectious Diseases|September 28, 2001
Level of maternal antibody required to protect neonates against early-onset disease caused by group B Streptococcus type Ia: a multicenter, seroepidemiology studyF Y Lin, J B Philips, P H Azimi, et al.
Zhonghua Liu Xing Bing Xue Za Zhi = Zhonghua Liuxingbingxue Zazhi|September 20, 2007
[Evaluation on the safety of a group A + C meningococcal polysaccharide vaccine]Bai-qing Dong, Qiang Ye, Xuan-lin Cui, et al.
Heliyon|July 23, 2020
The epidemiology of dengue outbreaks in 2016 and 2017 in Ouagadougou, Burkina FasoJustin Im, Ruchita Balasubramanian, Moussa Ouedraogo, et al.
The Journal of Infectious Diseases|December 8, 1998
Oral, inactivated, whole cell enterotoxigenic Escherichia coli plus cholera toxin B subunit vaccine: results of the initial evaluation in children. PRIDE Study GroupS J Savarino, E R Hall, S Bassily, et al.
Journal of Medical Microbiology|January 26, 2006
Multilocus sequence typing (MLST) analysis of Vibrio cholerae O1 El Tor isolates from Mozambique that harbour the classical CTX prophageJe Hee Lee, Kyung Ho Han, Seon Young Choi, et al.
The Pediatric Infectious Disease Journal|June 22, 2002
Introductory evaluation of an oral, killed whole cell enterotoxigenic Escherichia coli plus cholera toxin B subunit vaccine in Egyptian infantsStephen J Savarino, Eric R Hall, Samir Bassily, et al.
Statistics in Medicine|August 24, 2021
A Bayesian approach for estimating typhoid fever incidence from large-scale facility-based passive surveillance dataMaile T Phillips, James E Meiring, Merryn Voysey, et al.
BMC Infectious Diseases|May 17, 2019
Safety of a bivalent, killed, whole-cell oral cholera vaccine in pregnant women in Bangladesh: evidence from a randomized placebo-controlled trialAshraful Islam Khan, Mohammad Ali, Julia Lynch, et al.
Plos Neglected Tropical Diseases|March 13, 2015
Flexibility of oral cholera vaccine dosing-a randomized controlled trial measuring immune responses following alternative vaccination schedules in a cholera hyper-endemic zoneSuman Kanungo, Sachin N Desai, Ranjan Kumar Nandy, et al.
Plos Neglected Tropical Diseases|February 12, 2014
Mass vaccination with a new, less expensive oral cholera vaccine using public health infrastructure in India: the Odisha modelShantanu K Kar, Binod Sah, Bikash Patnaik, et al.
Pageof 44